North America Migraine Treatment Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 04-Jan-2020 | No of Pages: 100


USD 3995
USD 5795

Publish Date:


Total pages:


North America migraine treatment market is projected to register a CAGR of 11.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
North America migraine treatment Market, By Types of Migraine (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays And Others), Product Type (Prescription and Over The Counter), Type (Branded And Generic) End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the North America migraine treatment market are:

• Increasing prevalence of migraine
• Rising awareness programs
Market Players:
The key market players for North America migraine treatment market are listed below:
• Eli Lilly and Company
• Amgen Inc
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Allergan
• Abbott
• Allodynic Therapeutics, LLC
• AOBiome
• AstraZeneca
• Aurobindo Pharma USA (A Subsidiary of Aurobindo Pharma)
• Bausch Health Companies Inc
• Biohaven Pharmaceuticals
• Boehringer Ingelheim International GmbH
• Catalent, Inc
• Dr. Reddy’s Laboratories Ltd
• Impel NeuroPharma, Inc

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.